The world’s first widespread human testing of a flu vaccine which researchers hope will protect more over 65-year-olds against influenza has begun in the NHS.
More than 10,000 people aged 65 and over will be asked to take part in a study supported by the National Institute for Health Research (NIHR) and delivered by the University of Oxford in Berkshire and Oxfordshire. The recruitment target is 500. Researchers believe the vaccine could have a major impact on the worldwide fight against the virus, which affects about a billion people worldwide a year with 250,000 to 500,000 annual deaths, mainly in the over-65 age group. Current vaccines are only effective in 30 to 40% of over 65s as the immune system weakens with age and researchers believe the new vaccine could increase this. For those who receive the jab but still get the flu, researchers believe the new vaccine could also reduce the severity and duration of the illness.
It is believed the vaccine will offer a stronger protection against flu because it uses a different mechanism to get the body to protect against the virus. Under the microscope, the flu virus looks like a spherical cushion with lots of pins sticking out of it. The existing flu vaccines use surface proteins that lie on the outside of flu cells – the heads of the pins – to stimulate the body’s immune system to produce disease-fighting antibodies. But as the virus changes each year, so do the surface proteins, haemagglutinin and neuraminidase, meaning the flu vaccine needs to change too.
Global scientists therefore have to predict what each new annual strain of flu will look like. Unfortunately, sometimes by the time the vaccine has been made, the strain of virus that is causing illness has changed, and the vaccine doesn’t work well. The new vaccine is different as it uses the core proteins of the virus –inside the cushion – instead of the surface proteins. These core proteins remain virtually unchanged in all influenza A viruses, giving researchers the opportunity to create vaccines that will work against all of them. Humans get infected by both influenza A and B, but it is influenza A that causes the majority of severe illnesses and deaths.
Crucially, the new vaccine stimulates the immune system to boost influenza-specific T-cells, instead of antibodies, that kill the virus as it tries to spread through the body. Everyone has some influenza-specific T cells already, but numbers of them are often too low to be protective. Previous research found that these T-cells can help fight more than one type of flu virus, and researchers believe this means more people could be protected and the severity and duration of flu may be reduced.
About 10,000 over 65s registered at six GP practices will be asked to take part in the trial in Berkshire and Oxfordshire this winter. This includes 25 people who will be sought for extra blood tests at the university. They will receive the regular, annual immunisation in combination with the new vaccine, which has successfully undergone safety testing in 145 people, or the regular immunisation and a placebo shot, so the two can be compared. Patients will not be told whether they are receiving the new vaccine or placebo.
The vaccine was developed by Oxford University’s Jenner Institute with Vaccitech, a spin-out company from the institute. The study is being sponsored by Vaccitech and managed by the University’s Nuffield Department of Primary Care Health Sciences with support from the NIHR Clinical Research Network Thames Valley and South Midlands, a Department of Health-funded organisation which provides staffing to ensure research studies are run in the health service.
Professor Sarah Gilbert, Professor of Vaccinology at the University and co-founder of Vaccitech, said: ‘Every year, flu in older adults causes serious illness and sometimes death. We want to improve the situation, but in order to do that we need volunteers to help us test a new vaccine. If you are invited to take part, please consider doing so.’
Learn more: World-first trial for universal flu vaccine
The Latest on: Universal flu vaccine
- The pandemic is changing Hollywood, maybe foreveron November 26, 2020 at 12:10 pm
No New ‘Movies’ Till Influenza Ends” blared a New York Times headline on Oct. 10, 1918, while the deadly second wave of the Spanish Flu was unfolding.
- Hollywood changed by the pandemic, maybe foreveron November 26, 2020 at 8:47 am
No New ‘Movies’ Till Influenza Ends” blared a New York Times headline on Oct. 10, 1918, while the deadly second wave of the Spanish Flu was unfolding. A century later, during another pandemic, movies ...
- Does Mask Efficacy Justify Universal Mandates?on November 24, 2020 at 6:30 am
I have never thought that opposing mask mandates was a hill to die on, as the interference on personal liberty is relatively minimal. But I don’t think that universal mandates are justified ...
- Combination Covid-19 + Universal Influenza Vaccine: Vivaldi Biosciences Files Patent Applicationon November 23, 2020 at 1:31 pm
By NewsDesk @bactiman63 Vivaldi Biosciences, a clinical-stage biotechnology company developing genetically engineered intranasal vaccines for viral respiratory diseases, today announced it has filed ...
- Universal strikes another deal with a major theater chainon November 20, 2020 at 6:29 am
Another major movie theater chain has struck a deal with Universal Pictures to allow for shorter exclusive theatrical windows. Canada’s Cineplex has agreed on a multiyear “dynamic window” ...
- Quebec mother urging people to take pandemic, influenza seriously following death of toddleron November 19, 2020 at 4:40 pm
A Quebec mother is speaking out after her 3-year-old daughter died from influenza. “She was so lively. She danced, she moved, she talked a lot, she really had a lot of energy and then she died a few ...
- Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccineon November 19, 2020 at 5:50 am
Ii-Key-H1 vaccine in China Plans to incorporate Ii-Key-H1 vaccine into universal seasonal influenza vaccine MIRAMAR, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( (OTCQB ...
- Update: Quebec will soon have a test that detects COVID-19 and influenzaon November 17, 2020 at 11:39 am
A test that checks for COVID-19 and flu at the same time is on its way to Quebec. Pharmaceutical companies have developed so-called multiplex diagnostic tests that can detect COVID-19 and influenza, ...
- Transformative Influenza Vaccines Market, 2020 Report - ResearchAndMarkets.comon November 17, 2020 at 7:26 am
The "Transformative Influenza Vaccines, 2020" report has been added to ResearchAndMarkets.com's offering. Influenza causes respiratory diseases and often leads to large epidemics. Every year about 290 ...
- Why a Universal Flu Shot Could Help Cure Other Viruseson November 16, 2020 at 1:21 am
Influenza infects 1 billion people each year and its genetic shape-shifting means that vaccines aren't always effective. Scientists around the world are searching for a flu shot that will offer ...
via Google News and Bing News